CD36 and hematoma: Enhancing microglial/macrophage erythrophagocytosis throughactivation of TAM receptors, CD36, and TREM2 or inhibition of theSIRPα-CD47 pathway plays a central role in promoting hematoma clearanceand mitigating secondary brain injury.